Reshaping the Treatment Landscape in the Department of Veteran Affairs: Immunotherapy in Non-Melanoma Skin Cancer
Risk Assessment and the Role of Immunotherapy in Patients with cSCC

Questions marked with a * are required
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
Which of the following can be used for assessing risk for cSCC recurrence, metastasis or death?
Cemiplimab may be considered in patients who
What is your job role?
What is your type of practice?
How many years have you been in practice?
Please estimate the number of patients with or at risk for non-melanoma skin cancer that you provide for
Powered by QuestionPro